Effect of next generation pulsatile mechanical circulatory support on cardiac mechanics – The PULSE trial

We are pleased to announce our newest publication in the Cardiovascular Revascularization Medicine from the desk of Prof. Nicolas van Mieghem and Dr. Marcelo Bastos. MCS is increasingly used in the context of high-risk percutaneous coronary intervention (PCI). The effect of the pulsatile iVAC 2L MCS on left ventricular loading conditions and myocardial oxygen consumption (MVO2) is unknown. In this publication, the Erasmus University Medical Centre & Kings College London showcase their clinical experiences with the iVAC 2L device and outline the impact on patients with advanced coronary artery disease at high to prohibitive operative risk in their practice. Please check this link for the full publication.

Transcatheter Interventions Online 2022

PulseCath is proud sponsor of the Transcatheter Interventions Online 2022. It is a free international event broadcast, led by course director, Prof. Nicolas van Mieghem from Erasmus MC, Rotterdam, the Netherlands. On day 2 (24 March at 3 pm CET) the section High Risk & Complex PCI will take place including Mechanical Circulatory Support. A live case will be performed by the EMC, Rotterdam, the Netherlands.  For more information and registration.

Global Health & Pharma Magazine (GHP) awarded PulseCath

United Kingdom, 2022 – GHP has announced the winners of the Technology Awards. GHP awarded PulseCath with the Technology Awards for Best Global Circulatory Support System Manufacturer 2021. بطولات بايرن ميونخ We are really proud by receiving this award. Please check also the publication. In today’s digital age, technology plays a vital role in improving healthcare and helping health services to improve the quality of life and treatments that they are able to provide. Throughout the years, technology has evolved in the medical field from being able to provide 3D printing, to telehealth, robotic surgery and artificial organs, these advances have allowed the healthcare industry to excel in ways it could not before. GHP Awards Coordinator, Jazmin Collins has spoken about the success of the Awards programme: “Technology has evolved and has found a place in every single industry, healthcare being the most prominent as it has helped to save lives. […]

Congress CSI FOCUS D-HF in Frankfurt at December 10-11, 2021.

PulseCath is proud sponsor of the upcoming congress CSI FOCUS D-HF in Frankfurt at December 10-11, 2021. We would like to draw your attention to Friday 10th December to the presentation by Prof. Nicolas van Mieghem, Erasmus Medical Center, Rotterdam, The Netherlands: Insights from the PULSE Trial & iVAC 2L in MCS facilitated high-risk PCI. This is scheduled in the section Acute Mechanical Circulatory Support (15:40 – 17:10 CET). Want to learn more about iVAC 2L? Our experts are at your disposal at our booth. 

PulseCath named to MedTech Outlook’s Top 10 MedTech Startups in Europe 2021

PulseCath has been recognized as one of the “Top 10 MedTech Startups in Europe 2021”  by MedTech Outlook Magazine. “We take pride in honoring PulseCath as one among the 10 MedTech startups that are specialized in providing innovative healthcare solutions for respective companies,” said Alex D’souza, Managing Editor of MedTech Outlook. We are very proud with this recognization and the award. Please check also the interview online via this link. 

Huadong Medicine and PulseCath Announce Strategic Collaboration to Develop and Commercialize the iVAC mechanical circulatory product in Greater China

Partnership accelerates the development of the iVAC 2L mechanical circulatory device in Greater China. Expands Huadong Medicine’s medical portfolio for cases of high-risk PCI with innovative percutaneous ventricle assist devices based on innovative pulsatile technology. PulseCath will receive a significant investment in its share capital and in payments for regulatory and development activities and is eligible to royalties on iVAC’s commercial sales by Huadong Medicine in their commercial region. ARNHEM, THE NETHERLANDS and HANGZHOU, PRC, September 17, 2021 — PulseCath B.V., a leader in the expanding field of percutaneous ventricular assist devices for high-risk PCI, and Huadong Medicine Co., Ltd., today announced that the companies have entered into an exclusive collaboration to develop and commercialize the iVAC technology in mainland China, Hong Kong, Macau and Taiwan (Greater China) and selected other Asian Pacific countries. The collaboration agreement between PulseCath and Huadong provides Huadong Medicine with a license to distribute iVAC […]

Joint EAPCI/ACVC expert consensus document on pVAD

An expert consensus has been released by the Joint European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute Cardiovascular Care (ACVC) reviewing the pathophysiological context and indications for pVADs in different clinical settings. It also provides guidance regarding the clinical management of patients requiring pVADs. A quick overview is made on the state-of-the art of short-term mechanical circulatory support according to different indications. Additional discussions on the handling of complications, anticoagulation and weaning are also provided. The appendix section describes the theoretical basis for the use of different MCS devices, including how their effects differ. The review has been published on EuroIntervention. Please follow this link for the full publication.